|Day Low/High||11.20 / 11.56|
|52 Wk Low/High||6.07 / 13.76|
Until we see a session close below 1498.25, a near-term change in direction is unlikely.
These are quality stocks, and they'd be sure to fall on a military escalation with Iran.
Here's a quick roundup of earnings from stocks we've recommended. The news has been uniformly good.
In the healthcare sector, TMO and TEVA are well positioned to ride out the market's current volatility.
UnitedHealth and Cigna are compelling selections for exposure to this important sector.
As we near the year's halfway point, here is where I stand on STJ, MET, MS and TEVA.
The stock should climb much higher following the recent favorable court ruling.
TEVA's patents on Copaxone will be protected until 2015, resulting in additional billion in profits for the drug maker.
Secular trends appear likely to favor Mylan and Teva Pharmaceuticals.
There's no shortage of fear in the markets, but selling off quality stocks doesn't make sense right now.
These two beaten-down health care plays have low valuations but provide good long-term value and decent dividends.
Zynga reported earnings that were short of estimates in its first quarter as a publicly traded company.
Biotech is changing, so here's how to invest amid the industry's new gold rush.
Whether or not you believe the end is nigh, let's make as much money as possible beforehand.
The generic drug market looks strong over the long term and should continue to perform well in the future.
Despite Alcoa's earnings miss, the major indices are pointing toward a higher open.
While some are looking at gold as a bubble that has popped, the yellow metal has proven itself a strong asset class through bull and bear markets alike -- so it's an asset you want to own.